CAJ | 학술논문

目的评价光动力疗法联合Bevacizumab(Avastin)玻璃体腔注射治疗脉络膜新生血管疾病的疗效.方法对连续病例29例(29只眼)经光动力疗法(photodynamic therapy,PDT)联合Avastin玻璃体腔注射治疗的中心凹下或旁中心凹脉络膜新生血管(choroidal neovascularization,CNV)患者资料进行回顾性分析.其中年龄相关性黄斑变性(age-relatedmaculardegeneration,AMD)15例(15只眼),男性10例,女性5例,平均年龄为63.3岁,有2例曾接受1次光动力疗法,其余未接受任何治疗;特发性脉络膜新生血管(idiopathic choroidal neovascularization,ICNV)14例(14只眼),男性6例,女性8例,平均年龄为28岁,有1例曾接受2次光动力疗法,其余未接受任何治疗.所有患者在光动力疗法后1周内行Avastin玻璃体腔注射(1.5mg/0.06ml).疗效以视力稳定及再治疗次数作为标准.结果经3～6个月随访,29例患者中28例(96.5%)视力稳定或提高,27例(93.1%)视力提高.15例AMD患者中14例(93.3%)视力稳定或提高,13例(86.7%)视力提高,7例(46.7%)视力提高2行以上;1例(6.7%)治疗前后均为眼前指数的视力,1例(6.7%)视力从0.2降至0.1,病变稳定.10例(66.7%)通过一次联合治疗后CNV消退,随访期间较基线视力提高平均1.8行;3例(20%)3个月后需再次联合治疗.14例ICNV中14例(100%)视力稳定或提高,13例(92.8%)视力提高2行以上,随访期间较基线视力提高平均4.21行.13例(92.8%)通过一次联合治疗而使CNV消退.治疗及随访期间未见与PDT及Avastin相关的不良反应,亦未见眼内炎、眼压升高等并发症.结论本研究结果提示,PDT联合Avastin玻璃体腔注射治疗脉络膜新生血管的疗效显著,可以提高患者视力及减少再治疗次数.
목적 평개광동력요법연합Bevacizumab(Avastin)파리체강주사치료맥락막신생혈관질병적료효.방법 대련속병례29례(29지안)경광동력요법(photodynamic therapy,PDT)연합Avastin파리체강주사치료적중심요하혹방중심요맥락막신생혈관(choroidal neovascularization,CNV)환자자료진행회고성분석.기중년령상관성황반변성(age-relatedmaculardegeneration,AMD)15례(15지안),남성10례,녀성5례,평균년령위63.3세,유2례증접수1차광동력요법,기여미접수임하치료;특발성맥락막신생혈관(idiopathic choroidal neovascularization,ICNV)14례(14지안),남성6례,녀성8례,평균년령위28세,유1례증접수2차광동력요법,기여미접수임하치료.소유환자재광동력요법후1주내행Avastin파리체강주사(1.5mg/0.06ml).료효이시력은정급재치료차수작위표준.결과 경3～6개월수방,29례환자중28례(96.5%)시력은정혹제고,27례(93.1%)시력제고.15례AMD환자중14례(93.3%)시력은정혹제고,13례(86.7%)시력제고,7례(46.7%)시력제고2행이상;1례(6.7%)치료전후균위안전지수적시력,1례(6.7%)시력종0.2강지0.1,병변은정.10례(66.7%)통과일차연합치료후CNV소퇴,수방기간교기선시력제고평균1.8행;3례(20%)3개월후수재차연합치료.14례ICNV중14례(100%)시력은정혹제고,13례(92.8%)시력제고2행이상,수방기간교기선시력제고평균4.21행.13례(92.8%)통과일차연합치료이사CNV소퇴.치료급수방기간미견여PDT급Avastin상관적불량반응,역미견안내염、안압승고등병발증.결론 본연구결과제시,PDT연합Avastin파리체강주사치료맥락막신생혈관적료효현저,가이제고환자시력급감소재치료차수.
Objective To evaluate the preliminary results for patients treated with combined photodynamic therapy (PDT)with verteporfin and intravitreal bevacizumab (Avastin)for choroidal neovascularization (CNV)diseases.Methods This is a retrospective series of 29 cases (29 eyes)with juxtafoveal or subfoveal CNV. Patients were treated with PDT with verteporfin and 1.5 mg (0.06ml)of intravitrcal bevacizumab. Among them there were 15 cases of age-related macular degenerizatiun(AMD)with an average age of 63.3,of which 10 cases were male and 5 cases were female. Two cases of AMD accepted one PDT before treatment and the other were naive to treatment. Another 14 cases were the young patients with idiopathic CNV (ICNV)with an average age of 28, of which 6 cases were male and 8 cases were female. One case of ICNV accepted two PDT before treatment and the other were naive to treatment. All the patients